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Oncoviruses are collectively responsible for over 1,000,000 new cases of cancer per year; some can integrate
into the host’s chromosomes. The present work was aimed at assessing the proportion of transcriptionally
active viral integrants through a systematic review of the scientific publications present on the MedLine
database. From the articles screened, 628 viral integrants overall were retrieved, of which 530.84 were
transcriptionally active (84.53%); among the clinical samples, 264 of 323 integrants were active (81.73%).
The causes for the silencing were not addressed in the articles analyzed. These findings might highlight a
possible risk factor for the insurgence of cancer since some oncovirus integrants could be reactivated by
stimuli of disparate nature. Further studies should address such possibility.
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About 16% of all cancer cases have been identified having an infectious aetiology [1]. Hepatitis B virus (HBV),
human papilloma virus (HPV), human herpes 4 virus (HHV-4, historically known as Epstein–Barr virus [EBV])
and human herpes 8 virus (HHV-8, previously Kaposi sarcoma herpes virus) are collectively responsible for 56.2%
of the incident microbial-related cancer cases, corresponding to over 1,200,000 new cases per year [2].
HBV, HPV and HHV-4 share the capability of integrating into the host’s chromosomes whereas HHV-8
integrants have not been observed [3]. In addition, other DNA viruses with transformation potential can integrate:
Merkel cell polyomavirus (MCPV), human herpes 6 virus (HHV-6) and, in a lesser extent, adenovirus (AdV) [4–6].
The infection with these viruses is associated with a wide range of cancer types: HBV with hepatocarcinoma;
HPV with virtually all cases of cervical cancer and in a significant proportion of other tumors, for instance in the
head and neck; HHV-4 with a number of malignancies, in particular Burkitt and Hodgkin lymphomas, in both
immunologically deficient and competent patients; HHV-8 DNA has been retrieved in all Kaposi sarcoma lesions
even in immunocompetent hosts; MCPV is recognized as the causative agent of the Merkel cell carcinoma; HHV-6
has been involved in lymphoproliferative diseases; and AdV has been shown to transform rodent cells [1,7–9].
All these viruses encode for proteins that disrupt the cell cycle andDNAdamage repair response to sustain the viral
replication. For example, HBVX,HPV E6/E7, HHV-8 LANA andMCPV large T proteins, all hinder the function
of p53, a pivotal factor of the DNA damage response, and pRb, an oncosuppressor that prevents over-replication
of the cellular DNA [10–14]. HHV-4 encodes for a plethora of early proteins with oncogenic potential; for instance,
BARF1 and BCRF1 have antiapoptotic function and the viral DNAse enzyme can cause genomic instability,
therefore induction of the lytic cycle can contribute to the development of malignant phenotypes [15]. Even during
the lysogenic cycle, HHV-4 encodes for proteins and interfering RNAs that have oncogenic potential [16].
Integration can disrupt the transcriptional regulation of the viral oncogenes facilitating the insurgence of cancer.
For example, HPV integration, which is usually accompanied by the deletion of the open reading frame (ORF)
encoding the regulatory protein E2, is associated with overexpression of the oncoproteins E6 and E7 [5]. Usually
integration occurs in multiple viral copies per cell; for instance, an average 36 HHV-4 integrated viral copies per
cell have been identified in clinical samples [17]. A higher number of viral copies imply greater oncogene encoding
capability; however, overexpression of the oncoproteins might be deleterious even for the transformed cells and
an epigenetic silencing is typically established in order to avoid excessive cellular proliferation and consequent
senescence [18].
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Epigenetic silencing is reversible in nature and several studies have pointed out the dynamic aspects of the
epigenetic control [19]. It is feasible to assume that the transcriptionally silent integrants could be reactivated under
specific circumstances and they have been referred to as ‘selectable’ [16]. For instance, treatment of CaSki cells with the
methylation inhibitor 5-azacytidine resulted in the transcriptional activation of the selectable HPV integrants [18].
Similarly, HPV expression is blocked in nontumorigenic cells expressing the transcriptional repressors MCP-1 and
Jun/Fra-1 whereas it is active in the tumorigenic variants of the same cells that do not encode for these factors [20,21].
Increased calcium levels induced the exit from the latent cycle of the HHV-4-containing cell line Raji, although
this line is characterized by the coexistence of both integrative and episomal forms of the virus [22]. Modifications
of the cellular environment such as hypoxia and oxidative stress have been reported to reactivate transcriptionally
silent HHV-4 proviruses [23,24].
Since cells containing viral integrants are typically a minority within a tissue and, by definition, transcriptionally
silent viral copies do not expressmRNAs or proteins, screening assaysmightmiss the presence of the latent oncogenic
proviruses in a given sample. Likewise, the immune system is not activated due to the absence of sufficient levels
of viral antigens. Viral integrants have therefore the potential to remain unnoticed for long periods within a
tissue. Upon reactivation, selectable integrants could accumulate oncoproteins in the affected cells, beginning
the process of destabilization of the cellular biochemistry that might facilitate oncogenesis. Given this potential,
selectable integrants might represent a risk factor for the insurgence of cancer and their prevalence could have been
underestimated. The present study was carried out to appraise what proportion of viral integrants was actually
active within the infected cells in order to assess the feasibility of such risk.
Methods
The MedLine database was queried using the PubMed search engine with the following keywords:
(((( ((((((((((human papilloma?virus*) OR hpv?))) OR (((((Epstein–Barr virus*) OR HHV?4) OR human her-
pes?virus?4) OR hhv?4))) OR (((human herpes?virus?6) OR hhv?6))) OR ((((((kaposi?sarcoma?herpes?virus*) OR
kshv) OR human herpes?virus?8) OR hhv?8)))) OR ((((merkel?cell?polyoma?virus*) OR mcpv) OR mcpyv))) OR
(((adeno?virus*) OR adv))) OR (((hepatitis?b?virus) OR hbv)))) AND (((integra*) OR pro?vir*))) AND (((express*) OR
transcript*)))) NOT review[Publication Type].
The identified articles were imported into the Endnote version 7.5 [25] environment and screening of the
publications was performed within this platform. Duplicates and reviews were removed and only articles in English
language were selected; no limits of publication date were imposed. The articles were step-wise screened by title,
abstract and content. The eligibility criterion was the presence of data related to the genetic expression of viral
integrants; this was considered both in terms of viral mRNA detection or presence of viral proteins. Articles
regarding the use of AdV as a gene expression system were excluded from the present analysis. The samples reported
in the selected articles were also evaluated for the concomitant presence of episomal forms of the virus panel:
samples indicated to contain mixtures of viral integrants and episomes were excluded from this review. In cases
where multiple tests were used to assess the viral transcription, the assays providing higher transcription rate were
used in order to avoid overestimation of the proportion of silent integrants. Results were plotted using R version
3.3.3 [26].
Results
The MedLine database was queried on 7 December 2016 and 1791 articles were retrieved, with 2 duplicates. After
screening, 65 articles (3.63%) were selected because they contained information related to the genetic expression
from viral integrants; they all dated from 1982 onwards (Figure 1). The resulting data were stratified by sample
type, virus species and detection method (Table 1). The selected 65 articles were mostly related to HPV and HBV
(44.62 and 40.00%, respectively), followed by HHV-4 (7.69%), MCPV (4.62%) and HHV-6 (3.08%).
The cell lines, both primary and established, included in the present study were: 2.2.15 [27]; AM-HLH [28];
C4-I, C4-II, CaSki [29]; CU-VI-8 [30]; EC109 [31]; HeLa [29,32]; Hep3B [27,33]; hu-GK14 [34]; HX151c, HX155c,
HX156c, HX160c [35]; IB-4 [36,37]; Katata [38]; ME-180 [29]; MS1 [39]; MS-B6, MS-T6 [40]; MS751 [29,41]; NAB-
2 [42]; Namalwa-C18 [36]; Pal-1 [43]; PCL/PRF/5 [27]; QG-U, QG-H [44]; SiHa [29,45]; SKG-I, SKG-II, SKG-
III [44]; SNU-182, SNU-354, SNU-368, SNU-387, SNU-398, SNU-423, SNU-449, SNU 475 [46]; SNU-739,
SNU-761, SNU-878, SNU-886 [47]; UM-SCV-6 [48]; UD-SCC-2, UD-SCC-047 [49]; UPCI:SCC090 [50]; and
UPCI:SCC154 [49].
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Table 1. Proportion of transcriptionally active viral integrants. The samples bearing viral integrants and correlated with
expression data were stratified by sample type (cluster), viral species and detection methods.
Cluster Virus Detection method† Integrants VL range‡ Ref.
Physical status Viral expression Total Actives
Clinical samples HBV SB IHC 12 2 – [88]
SB NB 12 9 0.72–6 [89–92]
SB RT-PCR 28 19 – [51,93,94]
HPV APOT APOT 60 60 – [95,96]
DIPS RT-PCR 19 16 10−6–97 [79]
PCR IHC 6 1 10−7–217 [57]
PCR RT-PCR 138 130 0.14–62.29 [80,97–99]
SB APOT 9 9 – [52]
SB NB 8 2 1–100 [81,100,101]
SB RT-PCR 3 3 10−5–0.5 [102]
MCPV DIPS RT-PCR 2 2 10−3–0.5 [103]
From literature IHC 26 11 – [104]
Total 323 264 (81.73%) [34.65]
Primary cell lines HHV-4 FISH FISH 1 1 – [43]
HBV FISH RT-PCR 1 1 – [28]
SB NB 8 2 – [46]
SB RT-PCR 4 4 – [47]
HPV SB RPA 1 1 200–300 [48]
DIPS RT-PCR 1 1 – [30]
FISH RT-PCR 1 1 – [50]
SB NB 4 4 50–2000 [35]
HHV-6 FISH RT-PCR 1 1 – [38,40]
MCPV SB RT-PCR 2 1 1.7–3.5 [39]
Total 24 17 (70.83%) [425.87]
Established cell
lines
HHV-4 FISH FISH 2 1.84 – [36]
From literature RT-PCR 1 1 – [37]
Sequencing RT-PCR 1 1 1–4 [42]
HBV From literature NB 3 3 – [27]
SB NB 2 2 – [33,34]
HPV APOT RT-PCR 1 1 – [31]
DIPS APOT 3 3 0.5–11 [49]
From literature NB 1 1 – [32]
SB NB 13 12 – [29,41,44,45]
Total 27 25.84 (95.70%) [4.13]
Transfected cells HHV-4 FISH RT-PCR 1 1 – [61]
HBV FISH RT-PCR 192 192 – [56]
SB EIA 5 5 – [105]
SB IFA 1 1 – [60]
SB NB 3 3 1–222 [106–108]
SB RT-PCR 2 2 – [62]
HPV Sequencing RNA-seq 1 1 – [109]
SB NB 10 10 50–100 [59,110–112]
Total 215 215 (100%) [93.25]
Transgenic mice HBV SB NB 33 6 4–10 [53,54,58]
†APOT: Amplification of Papilloma Virus oncogene transcripts assay. DIPS: Detection of integrated papillomavirus sequences assay; EIA: Enzyme immune assay, including ELISA; FISH: Flu-
orescent in situ hybridization; HBV: Hepatitis B virus; HHV-4: Human herpes 4 virus; HHV-6: Human herpes 6 virus; HPV: Human papilloma virus; IFA: Immuno-fluorescence assay;
IHC: Immuno-histochemistry; MCPV: Merkel cell polyomavirus; NB: Northern blot; PCR: Polymerase chain reaction assay, including quantitative methods; RIA: Radio-immuno assay; RNA-
seq: mRNA deep sequencing; RPA: Ribonuclease protection assay; RT-PCR: Reverse-transcription PCR, including quantitative; SB: Southern blot; Sequencing: Both termination dye chemistry
and whole genome sequencing.
‡VL: Viral load, reported in virus copies per cell; averages values per cluster are given in square brackets.
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Table 1. Proportion of transcriptionally active viral integrants. The samples bearing viral integrants and correlated with
expression data were stratified by sample type (cluster), viral species and detection methods (cont.).
Cluster Virus Detection method† Integrants VL range‡ Ref.
Physical status Viral expression Total Actives
SB RIA 5 2 1–4 [55]
SB RT-PCR 1 1 – [113]
Total 39 9 (23.08%) [4.75]
Overall Total 628 530.84 (84.53%) [107.78]
†APOT: Amplification of Papilloma Virus oncogene transcripts assay. DIPS: Detection of integrated papillomavirus sequences assay; EIA: Enzyme immune assay, including ELISA; FISH: Flu-
orescent in situ hybridization; HBV: Hepatitis B virus; HHV-4: Human herpes 4 virus; HHV-6: Human herpes 6 virus; HPV: Human papilloma virus; IFA: Immuno-fluorescence assay;
IHC: Immuno-histochemistry; MCPV: Merkel cell polyomavirus; NB: Northern blot; PCR: Polymerase chain reaction assay, including quantitative methods; RIA: Radio-immuno assay; RNA-
seq: mRNA deep sequencing; RPA: Ribonuclease protection assay; RT-PCR: Reverse-transcription PCR, including quantitative; SB: Southern blot; Sequencing: Both termination dye chemistry
and whole genome sequencing.
‡VL: Viral load, reported in virus copies per cell; averages values per cluster are given in square brackets.
Overall the present analysis identified 628 viral integrants, of which 530.84 (84.53%) were transcriptionally
active; in other words, 15.47% of the integrants were silent. One study regarding HHV-4 reported that 90–92% of
the integrants in the screened cells were active [36]; the higher level was used herein to report the proportion of active
viral centers, hence the fractional number. Among the clinical samples, MCPV was the least active: 46.43% of the
viral integrants were shown to be transcriptionally active compared with the 57.69% of HBV and the 89.96% of
HPV. Among the established cell lines, the expression rate was virtually complete (95.70%). In the primary cell
line group, there were two instances where a quarter and a half of the integrants were transcriptionally active for
HBV [46] and MCPV [39], respectively, whereas all the other cases were fully expressed; consequently the overall
proportion of active integrants for this group was 70.83%. The transgenic mice had the lowest proportion of
transcriptional activity (23.08%) in comparison to the other clusters and were infected only with HHV-4.
There were instances where the integrants were transcribing only some of the ORFs under evaluation. One study
regarding HBV reported 11 out of 22 integrants as transcriptionally active (50.00%) based on the expression of
the S gene, but only 4 (18.18%) were expressing the surface antigens (HBsAg) [51]. Transcription of the X gene
was observed in two out of eight (25.00%) cell lines analyzed, but none expressed the S gene [46]. Nine out of nine
(100%) HPV integrants were expressing E6 mRNAs but only seven (77.78%) were also transcribing for messenger
RNAs bearing E7 [52]. Other studies reported integrants active only in certain tissues: in transgenic C57BL/6 mice,
HBV particles or HBsAg were expressed in various amounts and in distinct sites in different subjects [53,54].
Some of the works gathered in the present review were the first experimental models aimed at addressing the
oncogenic potential of HBV in vivo [53–56]. Such models recorded the vertical transmission of integrants through the
germ line; remarkably, one lineage of silent integrant produced a progeny with integrants transcriptionally active in
some mice and inactive in others. In the latter group, duplication of the parental viral sequence was observed and
the ORF encoding the surface antigen was maintained intact. It was suggested that HBV could contain a promoter
with sequences activated only in the liver and kidney due to the high amount of HBsAg often observed solely in
those tissues but other results showed that, in some mice, the expression of the surface antigen could also peak in
the heart and stomach. These studies also highlighted the absence of both immune response against HBsAg and
signs of hepatitis in the progeny of the transfected mice; the viral antigen was postulated to be recognized as self
in the mice and therefore no immune response was activated that could damage the liver. Vertical transmission in
mice of integrated HBV was reported [56].
A selectable HHV-6 integrant was activated using either 12-O-tetradecanoyl-phorbol-13-acetate (TPA) or
calcium ionophores [38]. This was obtained in the cell line Katata, which was derived from a Burkitt’s lymphoma
sample. Katata cells do not contain EBV contaminants and HHV-6 was identified as a single copy integrant (type
I) located on chromosome 22. The reactivation of the virus was postulated to be dependent on protein kinase C
(PKC): TPA is a direct stimulator of PKC and PKC is also activated by increased intracellular calcium levels. No
infectious HHV-6 particles were produced after reactivation.
Overall the viral load (VL) of the samples gathered in the present study ranged between 10−7 and 103 copies
per cell [35,57], being highest in the primary cell lines and lowest in the established cell lines. Some studies reported
either the number or the location of the integration sites, which ranged between 1 and 2 [28,33,40,41,43,45,51,58–62].
10.2217/fvl-2017-0063 Future Virol. (Epub ahead of print) future science group



















1982 1984 1985 1986 1987 1988 1989 1992 1994 1995 1997 1998 1999 2000 2002 2003 2004 2006 2007 2008 2009 2011 2013 2014 2015 2016
Figure 1. Stratification by year and virus species of the scientific publications assessed in the present review. Bar plot representing the
number of articles including data regarding the expression from viral integrants (n = 65); bars are colored according to the legend.
Remarkably, an HPV integrant with 217 copies was reported being transcriptionally silent; it was not indicated
whether the HPV sequences were dispersed in more than one integration site [57].
The data regarding the integration sites were limited and did not provide information regarding a possible
association between the targeted locus and transcriptional status of the provirus; neither was present a description
of the chromatin context of the targeted loci. The effect of the viral integration on the expression status or phenotype
of the host cell also could not be easily extrapolated. A list of the integration loci described in the retrieved articles
is given in the Supplementary Table 1.
The articles selected in the present meta-analysis spanned four decades; the attempt to understand whether
increases in analytical sensitivity had affected the detection of silent integrants was hampered by the heterogeneity
of the data (Table 2). The proportion of transcriptionally active integrants ranged from 16.67 to 100% and overall
increased steadily from 67.78% in the 1980s to 92.29% in the 2010s. In particular, the combination of Southern
blot and Northern blot detected 50% of active integrants in the decade of the 1980s, 57.14% in the 1990s and
100% in the 2000s, but was not applied in the 2010s. However, even the number of samples analyzed by the
Southern/Northern blot combination decreased from 74 in the 1980s to 5 in the 2000s, hence it was not possible
to draw any reliable statistical conclusion from these data.
Discussion
The present study sought to determine what proportion of oncogenic proviruses might be actually transcribing in
the infected cells in order to assess whether silent copies of the integrants could be present in a given specimen. In
clinical samples, such presence might constitute a risk factor for the insurgence of cancer since selectable viruses
could be reactivated by several cellular stimuli at some point after the event of integration. These latent proviruses
might be difficult to identify during screening.
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Table 2. Detection of transcriptionally active integrants by publication period.
Period Detection method Integrants Ref.
Physical status Viral expression Total Actives
1982–1990
(67.78%)
From literature NB 1 1 (100%) [32]
SB IFA 1 1 (100%) [60]
SB IHC 12 2 (16.67%) [88]
SB EIA 5 5 (100%) [105]
SB NB 74 37 (50.00%) [29,35,44,45,53,54,
58,89,90,92,100,101,
106,108,111,112]
SB RIA 5 2 (40.00%) [55]
1991–2000
(83.19%)
FISH FISH 2 1.84 (92.00%) [36]
FISH RT-PCR 2 1 (50.00%) [38,40]
From literature NB 3 3 (100%) [27]
SB NB 14 8 (57.14%) [33,34,41,46,59,81,91]
SB RPA 1 1 (100%) [48]
SB RT-PCR 10 10 (100%) [47,62,93]
2001–2010
(85.57%)
FISH FISH 1 1 (100%) [43]
APOT APOT 3 3 (100%) [96]
FISH RT-PCR 193 193 (100%) [50,56]
From literature RT-PCR 1 1 (100%) [37]
PCR IHC 6 1 (16.67%) [57]
SB NB 5 5 (100%) [107,110]
SB RT-PCR 28 19 (67.86%) [51,94,102,113]
Sequencing RT-PCR 1 1 (100%) [42]
2011–2016
(92.29%)
APOT APOT 57 57 (100%) [95]
APOT RT-PCR 1 1 (100%) [31]
DIPS APOT 3 3 (100%) [49]
DIPS RT-PCR 22 19 (86.36%) [30,79,103]
FISH RT-PCR 2 2 (100%) [28,61]
From literature IHC 26 11 (42.31%) [104]
PCR RT-PCR 138 130 (94.20%) [80,97–99]
SB APOT 9 9 (100%) [52]
SB RT-PCR 1 1 (100%) [39]
Sequencing RNA-seq 1 1 (100%) [109]
The retrieved articles are stratified by publication year into different decades (period) and by detection method. The average proportion of transcriptionally active integrants for each
decade is given in brackets.
APOT: Amplification of Papilloma virus oncogene transcripts assay. DIPS: Detection of integrated papillomavirus sequences assay; EIA: Enzyme immune assay, including ELISA; FISH: Flu-
orescent in situ hybridization; IFA: Immuno-fluorescence assay; IHC: Immuno-histochemistry; NB: Northern blot; PCR: Polymerase chain reaction assay, including quantitative methods;
RIA: Radio-immuno assay; RNA-seq: mRNA deep sequencing; RPA: Ribonuclease protection assay; RT-PCR: Reverse-transcription PCR, including quantitative; SB: Southern blot;
Sequencing: Both termination dye chemistry and whole genome sequencing.
The information regarding the proportion of actively transcribing integrants was obtained by a meta-analysis of
scientific publications retrieved from the MedLine database. The results gathered in the present study showed that
overall about 85% of the integrants were expressing viral genes; in the clinical samples, the ratio was even lower
(∼82%). The data were based mostly on HPV and HBV; the lack of publications regarding HHV-8 and AdV
might confirm the absence of integration of these viruses, particularly in clinical samples. The seminal work carried
out by Doerfler and collaborators has highlighted the consequences of AdV type 12 integration on the viral and
cellular transcription following the epigenetic response of the cell to integration [63,64]. However, in more recent
years, this line of research has been replaced by a more heterogeneous use of AdV type 12 as a gene delivery system;
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these articles were not included in the present meta-analysis because they dealt with genes not originally present in
AdV.
One article collected herein reported a silent HHV-6 integrant becoming transcriptionally active after modifying
the cellular environment [38], supporting the case for a delayed viral reactivation. Reactivation of HHV-6 integrants
has also been reported during coinfection with Chlamydia trachomatis and in immunocompromised patients [65,66].
Although no infectious particles were produced in both cases, possibly due to loss of information in the flanking
repeated sequences that might affect viral assembly, excision of the viral integrants with generation of circular
episomes with transcriptional capability was observed. Restoration of transcription from integrated and excised
HHV-6 genomes has been linked to pathologies such as angina pectoris and it has been suggested that the process
of integration and excision could facilitate the insurgence of senescence and chromatin instability in the affected
cells [67]. Even in absence of viral particles, reactivation of HHV-6 integrants can be considered a risk factor for
the insurgence of several pathologies including cancer. The reactivation of HHV-6 in the mentioned paper was
obtained by modifying the cellular calcium level exposing the cell to either TPA or ionophores; ultimately, PKC was
regarded as involved in the termination of the silencing pathway [56]. PKC has been also involved in the reactivation
of latent EBV in the cell line Raji [22].
Latency could facilitate the dissemination of the HHV-6 integrants and eventually lead to their fixation in
the human population. In the case of human immunodeficiency virus (HIV), the evolutionary advantage of
transcriptional silencing is not immediately evident: latency is an inherent biochemical activity of HIV that pre-
dates the advent of antiretroviral therapies, thus it must have an advantage in the natural history of the infection;
however the gain is not apparent for a virus whose basic reproductive strategy is based on progeny with high VLs [68].
HIV has been suggested to be capable of surviving adverse physiological conditions and inefficient transmission by
shielding itself in a small subset of lymphocytes as inactive provirus [68]. Similarly, HHV-6 could remain hidden in
the cells, diffuse vertically and become activated when the cellular environment is modified. However horizontal
transmission is expected to be precluded for the integrants since the excited viral genomes will lack information
at the genome’s extremities with respect to the parental episomal virus. HHV-6 integration is due to regions of
homology to the human telomeres in the viral terminal repeats that are also present in human herpes 7 virus
(HHV-7) and Merek disease virus (MDV) [69–71]; however, HHV-7 is not found integrated whereas HHV-6 and
MDV are retrieved as integrants [72]. Further work is required to determine the molecular differences that set apart
HHV-7 from HHV-6 and MDV.
The present meta-analysis identified publications regarding mice models that reported the transmission of
integrated HBV from spermatozoa to the oocyte with generation of carrier embryos [53–56]. Vertical transmission
of HBV is a recognized route of dissemination of HBV, however this modality normally involves infectious
particles [73]. These aforementioned studies reported in vitromodels where integration was obtained by transfecting
a plasmid into spermatozoa; nevertheless, integrated HBV genomes have been retrieved in the semen of human
patients [74]. Since integrated HHV-6 can also be vertically transmitted via germ line [5], it can be speculated
that integrated oncoviruses could be disseminated not only by infection and their prevalence could be wider than
currently assumed.
The data collected herein were disparate in terms of viral species, samples and detection method; stratification
into clusters was carried out in order to define patterns that could help understand the viral behavior. These clusters
had different bias toward viral integration: transgenic mice and transfected cells are actively screened for the presence
of active integrants; clones of cell within a line are selected due to their replication rate and the viral expression
might provide an advantage in vitro. Henceforth, it was not surprising that the cell lines, particularly the transfected
ones, had the highest proportion of active integrants among the clusters analyzed herein. Clinical samples and in
a lesser extent, primary cell lines provided a better understanding of the viral biology in physiological conditions.
However the samples gathered in the present study varied in terms of gender, age, ethnicity, length of infection,
previous pathologies and presence of other risk factors. Nevertheless, these disparities provided a snapshot of the
viral biochemistry under several conditions and the results suggested that each of the oncoviruses included in the
present work had the potential to generate silent integrants.
In addition, the analytical tools were diverse and with a different bias toward detection of active integrants.
For instance, the amplification of papillomavirus oncogene transcripts (APOT) assay specifically amplifies viral
messengers from transcriptionally active integrants but cannot detect the integrants directly [52], therefore silent
integrants are missed. On the other end, detection of integrated papillomavirus sequences (DIPS) is used to
characterize the sequence structure of the viral integrants, particularly at the virus–cell junctions, but it is not
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designed to query the transcriptional activity [75], thus it cannot assess the expression status of the proviruses.
The combination of APOT and DIPS was applied only once in the studies collected herein [49]. The nucleic
acid amplification and blotting methods act on populations of cells and do not have the resolution to assess the
transcriptional activity of individual integrants. Fluorescent in situ hybridization (FISH) has single cell resolution
but has limited throughput therefore it is likely to miss rare integrants during screening procedures. Nonetheless,
VL was never assessed by FISH in the scientific publications gathered in the present study, suggesting that despite
its single-cell resolution, this technique is not suitable for quantitative purposes.
Moreover, the techniques were applied in different decades and a bias toward increased analytical sensitivity
must be considered. The average proportion of active integrants increased with the publication year; such result
could be an artefact of the clustering method used to report the data. Further work is required to assess whether the
analytical sensitivity had changed the detection of viral integrants and their transcriptional status in recent years.
Most of the retrieved articles did not report VL data, thus it was not possible to assess whether the oncogene
expression was derived from a single viral center or from a pool of proviruses. The VL from the retrieved scientific
articles spanned ten orders of magnitude; despite such wide range, some observations could be made. Very low VLs
could simply imply that few cells containing high amounts of virus were present in a background of neutral cells; the
actual VL in these ‘jackpot’ cells [76] was unknown. These potential reservoir cells with high VL might be present in
a given tissue at low concentration; should the number of noninfected cells be great enough, it is feasible to assume
that their presence could be masked and their activity remain undetected. In cell lines, neutral cells are typically
depleted, therefore the VL is expected to be higher than in clinical samples; counter-intuitively, though, the VL of
the established cell lines was lower than that of the primary cells and clinical samples. It might be postulated that
in the established lines, cells with few active proviruses were selected in order to provide the right amount of viral
proteins to stimulate the cell replication without triggering senescence, as previously suggested [18]. In primary cell
lines and clinical samples, such selection could not have been fully unfolded, explaining the higher VL. Among the
articles retrieved in the present review, there were no follow-up studies that could assess the dynamics of VL along
the passaging of primary cell lines and their evolution toward established cell lines, thus this interpretation could
not be tested.
The identification of a silent integrant does not imply the presence of a selectable integrant. The recombination
mechanism that is involved in the integration phase is usually accompanied by loss of sequences in both the host’s
chromosomes and in the viral genome [77]. As a consequence, the integrant might lose its promoter region and
become transcriptionally incompetent. Tandem integrants (type II) such as head and tail concatenamers are highly
likely to contain intact, thus transcriptionally competent, viral sequences while having disruptions only at the
extremities of the array. In addition, a recent work has shown that tandem HPV integrants can behave as enhancers
for the transcription of the viral oncogenes [78], thus type II integrants are expected to have transcriptional capability
and high expression rate. On the other hand, transcription from individual integrants (type I) might be assumed
to be restricted by the functional integrity of the viral sequence, although host’s promoters might compensate for
the loss of the viral ones. There was no direct data in the present work that could corroborate such assumption: the
scientific publications recording clinical samples with high viral copy number only reported the VL data for the
overall group rather than for each sample, therefore it was not possible to assess whether there was a relation between
viral copy numbers and transcriptional status [79–81]. Furthermore, it has been suggested that type II pro-viruses
might undergo epigenetic silencing [19]; this process can overcome the physical status of the integrants and disrupt
an association between VL and transcriptional activity.
Ultimately, the actual expression profile of a given integrant is due to its chromatin conformation [82], which
can be altered by epigenetic mechanisms such as the methylation status of the viral sequences; however the studies
collected herein did not include an epigenetic analysis. It would have been interesting, for instance, to assess whether
the transcriptionally inactive integrant with a VL of 102 identified in a clinical samples [57] was silent because of
epigenetic suppression or for other reasons such as loss of the viral promoter. Remarkably, transgenic mice showed
the lowest proportion of actively transcribing proviruses, clearly indicating that despite bearing at least one copy
of integrated virus in each cell, the viral genetic expression was modulated by the cellular environment; epigenetic
mechanisms were evoked to explain the transcriptional silencing [53,54].
It is logical to assume that only a subset of the transcriptionally silent integrants identified in the present study
were truly selectable in nature. Nevertheless, given the high prevalence of infection of the viruses included in this
review [83] and the non-negligible proportion of silent integrants identified herein, which ranged from one in five
to one in ten of all integrants, it is possible that a significant number of people could carry selectable integrants.
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These viruses could be expected to be difficult to identify by routine diagnostic and reactivate years after the actual
infection, so that the clinical features that could facilitate the diagnosis might be forgotten.
Based on these data, two speculative scenarios can be drawn. In the first one, a subject becomes infected
horizontally via the typical routes of transmission of the oncoviruses; integration might occur in a small subset
of cells within a given tissue. The provirus could remain occult for a certain amount of time until a cellular
stimulus would trigger an environmental modification, reactivating the expression of viral oncogenes, facilitating
the development of the malignant phenotype as a result. Latent rare integrants are expected to be a minority within
a tissue, so their presence would likely be missed by screening tests. For instance, a limit of detection of one genome
equivalent per microliter of sample and a minimum of 20% integration were reported for assays assessing VL and
physical status of HPV, respectively [84]; for HBV testing, the recommended VL cutoff is in the range of 1–1000
genome equivalents per microliter of samples [85]. Specimens containing very low amounts of viral genomes that
are formed by a limited number of cells with high VL among a high number of neutral cells or where few integrants
are coexisting with many native episomal forms of the virus would be likely to give a false negative result during
screening testing. In addition, since the reactivation would appear a long time after the infection, it is plausible to
assume that no specific tests targeting oncoviruses would be implemented and the presence of the integrants might
remain undetected. The immune response, in particular the action of interferon, is able to deplete viral episomes
from the infected cells [86]; however integrants cannot be removed by this mechanism and can therefore persist after
viral clearance. Interestingly, it has been reported that interferon can facilitate viral integration [87].
The second scenario is more difficult to define and it is based on the vertical transmission of oncoviruses via
germ line. This is a recognized route of infection of HHV-6, which is characterized by abnormal high VL in serum
samples and that has resulted in mistreatment of patients [8]. The outcome of this modality of infection can be
outlined using the HBV mice models [54–56]. Should viral sequences be present in every cell of a subject rather
than within a single tissue, it should be relatively easy to identify the presence of the oncoviruses by molecular
biology assays. On the other hand, the presence of viral antigens that could be produced in low quantities in fetuses
and newborns would be recognized as self by the immune system; consequently detection of the virus by serology
assays might be affected. Probably the reactivation of these constitutive proviruses would occur only in specific
tissues rather than being disseminated, in which case the two scenarios will essentially converge. In both scenarios,
selectable integrants might facilitate the insurgence of the malignant phenotype and therefore represent a risk factor
for the development of cancer.
Conclusion
The present study was aimed at assessing what proportion of oncogenic viral integrants was actively transcribing;
this task was addressed by a meta-analysis of the literature present on the MedLine database. The data showed that
about 85% of the integrants were actively expressing viral products. The converse implied that about one in five
to one in ten of the integrants could be in a state of transcriptional latency. The data collected could not explain
the reasons for the transcriptional inactivity of these proviruses. The presence of a non-negligible proportion of
oncogenic viruses that could integrate and remain transcriptionally silent until reactivated by a cellular stimulus
might represent a risk factor for the insurgence of several types of cancer. Further studies are needed to assess
whether such risk has a statistical and clinical foundation.
Future perspective
The data collected in the present review highlighted the possibility of the presence of selectable oncovirus integrants
in the general population. The vast majority of the articles collected herein were focused on HBV and HPV. More
studies related to the other oncoviruses with integrative capabilities might elucidate the mechanism of integration
and assess whether a common pathway is present. For instance, one answer that future work could address is
why these viruses show such differences in the frequency of integration. Both HHV-4 and HHV-8, like the
other members of the Herpesviridae family, have a linear genome that could, in theory, lead to recombination;
nevertheless, the former has been reported as a provirus only in cell lines whereas the latter has not been identified
in the integrative form at all. HBV, HPV andMCPV possess circular DNA genomes and such feature could explain
why these viruses have a higher frequency of integration than the herpeviruses. This is a somewhat counter-intuitive
concept: first, circular DNA is less prone to integration, hence HBV, HPV and MCPV should integrate less than
the herperviruses; second, the genomes of the herpeviruses are recircularized in the nucleus of the infected cells,
thus they should undergo the same mechanisms and frequencies of integration of HBV, HPV and MCPV. HHV-6
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is a peculiar virus that, due to the sequences with telomeric homology present in its genome follows a separate
pattern of integration than the other viruses included in the present review.
In recent times, the combination of whole genome sequencing and RNA-seq analysis has become more and
more common. Such approach provides valuable description of the viral integrants in terms of their mutations, loss
of coding sequences and acquisition of cellular promoters’ control over transcription; the mRNA data complement
the picture indicating which integrants are actively transcribing. It can be anticipated that in the forthcoming years,
more emphasis will be given to longitudinal studies that will focus on the nontranscribing integrants to understand
whether they might be activated upon given cellular stimuli. Methylation status and chromatin conformation will
also provide useful information regarding the mechanisms of latency.
More studies are required to assess the true prevalence of latent oncovirus integrants; given the expected rarity of
the integration events and the absence of viral transcription, the screening methods should be aimed at analyzing
high number of cells within a specimen and should have high sensitivity. PCR methods are characterized by
high analytical sensitivity but should be coupled by selection methods that could reduce the bias introduced by
noninfected cells. Single-cell PCR is a possible approach for such screening; flow-FISH is another possible way, the
latter taking advantage of the high-throughput of the flow cytometer assay with the single cell resolution of the
FISH assay.
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Summary points
 DNA viruses with oncogenic potential have been reported to be integrated in cell lines and clinical samples. Not
all oncovirus integrants are transcriptionally active.
 Although in some cases transcriptional inactivity could simply be due to rearrangement of the viral sequences
that resulted in the loss of regulatory or oncogene sequences, in other cases a true latency might have been
established. Transcriptionally competent virus integrants in latent state have been defined as ‘selectable’.
 Transcriptional silencing is obtained through epigenetic mechanisms, which are reversible. Several factors can
trigger the modification of the epigenetic pressure on the viral integrants inducing reactivation of the expression
of oncogenes, facilitating the insurgence of cancer.
 The present review of scientific publications present in the MedLinedatabase assessed that 84.53% integrants
were actively transcribing for viral products; in clinical samples alone, the proportion of transcriptionally active
integrants fell to 81.73%. The results implied that the remainder of the integrants were either in a status of
latency or incapacitated to transcribe, although the articles analyzed did not address the reasons of the
transcriptional silencing.
 Given the high prevalence of the oncoviruses infections, even if a fraction of the silent viral copies observed
herein represented genuine selectable integrants, it can be speculated that a non-negligible proportion of the
population might carry viral oncogenes that could be reactivated by a plethora of cellular stimuli. Therefore,
these selectable viral integrants might represent a potential risk factor in oncogenesis.
 Further studies are required to assess whether this potential risk is concrete.
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